![]() |
David R. Raleigh, M.D., Ph.DAssistant Professor
|
Professional Focus
Dr. Raleigh is specialized in the treatment and investigation of central nervous system tumors in adult and pediatric patients. His research focuses on the biologic processes that cause brain tumors to grow. His primary goal is to understand how developmental signaling pathways cause cancer to shed light on the fundamental mechanisms of developmental biology and identify novel treatments for cancer patients. His laboratory research makes use of biochemistry, molecular biology, cell biology, mouse genetics, genomics, bioinformatics and pharmacology to gain new insights into the molecular determinants of human malignancies.
Education
2000-2004 | University of California, Berkeley | BA (Honors) | Molecular and Cell Biology |
2000-2004 | University of California, Berkeley | BA (Honors) | Cognitive Science |
2005-2012 | University of Chicago | Medical Doctorate | Pritzker School of Medicine |
2007-2010 | University of Chicago | Doctorate of Philosophy | Pathology |
2005-2012 | University of Chicago | MD/PhD Student | NIH MSTP |
2012-2013 | Kaiser Permanente Santa Clara | Intern Physician | Internal Medicine |
2013-2017 | University of California, San Francisco | Resident Physician | Radiation Oncology |
2015-2016 | University of California, San Francisco | Chief Resident Physician | Radiation Oncology |
Professional Experience
2017-present | University of California, San Francisco | Assistant Professor | Radiation Oncology |
2017-present | University of California, San Francisco | Principal Investigator | Brain Tumor Center |
2017-present | Children’s Oncology Group | Principal Investigator | ANBL 1232 |
Awards & Honors
2001-2004 | Dean’s Honor Roll, UC Berkeley College of Letters and Science |
2004 | Graduation with High Honors, UC Berkeley Department of Molecular Cell Biology |
2004 | Graduation with High Honors, UC Berkeley Department of Cognitive Science |
2004 | Phi Beta Kappa Inductee, UC Berkeley |
2009 | Travel Award, FASEB Gastrointestinal Tract XIII Annual Meeting |
2009 | Poster of Distinction, Digestive Disease Week Annual Meeting |
2009 | Outstanding Oral Presentation, U Chicago Annual Biomedical Sciences Cluster Retreat |
2010 | Takeda Travel Award, Experimental Biology Annual Meeting |
2011 | Top Quartile in Graduating Class, U Chicago Pritzker School of Medicine |
2011 | Career Development Award, U Chicago Medical Scientist Training Program |
2012 | Outstanding Performance, U Chicago Department of Radiation and Cellular Oncology |
2013 | Teaching Award, Kaiser Permanente Santa Clara |
2013-2017 | ABR Holman Research Pathway, UCSF Department of Radiation Oncology |
2015 | Resident Research Travel Award, UCSF Clinical & Translational Science Institute |
2016 | Semi-Finalist, Burroughs Wellcome Fund Medical Scientist Career Award |
2016 | Roentgen Research Award, Radiological Society of North America |
2016 | Biology Abstract Travel Award, American Society for Radiation Oncology Annual Meeting |
2016 | Poster of Distinction, Association of Residents in Radiation Oncology |
2016 | Top Young Investigator Awardee, ASCO Scientific Career Development Retreat |
2016 | PSSP Scholar, UCSF Physician Scientist Scholar Program |
2017 | Young Oncologist Travel Grant, American Radium Society Annual Meeting |
2017 | Poster of Distinction, American Radium Society Annual Meeting |
Recent Significant Publications :
Raleigh DR, Algazi A, Arron ST, Neuhaus IM, Yom SS. Induction hedgehog pathway inhibition followed by combination modality radiotherapy for basal cell carcinoma. Br J Dermatol. 2015. 173:544-546. PMID: 25702621.
Oskvarek JJ, Brower JV, Mohindra P, Raleigh DR, Chmura SJ, Golden DW. Educational impact of a structured radiation oncology clerkship curriculum: an inter-institutional comparison. J Am Coll Radiol. 2016. 16: 30632-30639. PMID: 27652570.
Magill ST, Lau D, Raleigh DR, Sneed PK, McDermott MW. Surgical resection and interstitial 125I brachytherapy for high grade meningioma: a 25 year series. Neurosurg. 2017. 80:409-416. PMID: 27258768.
Raleigh DR†, Solomon DA†, Lloyd SA, Lazar A, Garcia MA, Sneed PK, Clarke JL, McDermott MW, Berger MS, Tihan T, Haas-Kogan DA. Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. Neuro Oncol. 2017. 19:78-88. PMID: 27282397.
Garcia MA, Lazar A, Duriseti S, Raleigh DR, Hess C, Fogh SE, Barani IJ, Nakamura JL, Larson DA, Theodosopoulos P, McDermott MW, Sneed PK, Braunstein SE. Discovery of additional brain metastases on the day of stereotactic radiosurgery: risk factors and outcomes. J Neurosurg. 2017. 126:1756-1763. PMID: 27367235.
Raleigh DR, Seymour ZA, Tomlin B, Theodosopoulos PV, Berger MS, Aghi MK, Geneser SE, Krishnamurthy D, Fogh SE, Sneed PK, McDermott MW. Resection and brain brachytherapy with permanent iodine-125 seeds for brain metastasis. J Neurosurg. 2017. 126:1749-1755. PMID: 27367240.
Raleigh DR, Tomlin B, Del Buono B, Roddy E, Sear K, Byer L, Felton E, Banerjee A, Torkildson J, Samuel D, Horn B, Braunstein SE, Haas-Kogan DA, Mueller S. Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients. J Neurooncol. 2017. 131:359-368. PMID: 27778212.
Kline CN, Joseph NM, Grenert JP, van Ziffle J, Talevich E, Onodera C, Aboian M, Cha S, Raleigh DR, Braunstein SE, Torkildson J, Samuel D, de Alba Campomanes A, Banerjee A, Butowski N, Raffel C, Tihan T, Bollen AW, Phillips JJ, Korn M, Yeh I, Bastian BC, Gupta N, Mueller S, Perry A, Nicolaides T, Solomon DA. Targeted next-generation sequencing of pediatric brain tumor patients improves diagnosis, identified pathogenic germline mutations, and directs targeted therapy. Neuro Oncol. 2017. 19:699-709. PMID: 27978508.
Braunstein SE†, Raleigh DR†, Bindra R, Mueller S, Haas-Kogan DA. Pediatric high grade gliomas. J Neurooncol. In press.
Vasudevan HN†, Raleigh DR†, Johnson J, Garsa AA, Theodosopoulos PV, Aghi MK, Ames C, McDermott MW, Barani IJ, Braunstein SE. Management of chordoma and chondrosarcoma with fractionated stereoetactic radiotherapy. Neurosurg Focus. In press.